Novel biomarkers and genomic tests in prostate cancer: A critical analysis

Minerva Urologica e Nefrologica

Volumn 67, Issue 3, 2015, Pages 211-231

  Falzarano, S M ^a   Ferro, M ^b   Bollito, E ^c   Klein, E A ^a   Carrieri, G ^d   Magi Galluzzi, C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Department of Pathology ^*  (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Biological markers; Genomics; Prostatic neoplasms

Indexed keywords

ALPHA ACTININ 1; ALPHA2 GLYCOPROTEIN 1; ANDROGEN RECEPTOR; APOLIPOPROTEIN; BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CELL CYCLE PROTEIN 20; CYCLIN DEPENDENT KINASE 1; FORKHEAD BOX PROTEIN M1; KALLIKREIN; MITOCHONDRIAL DNA; NUCLEAR FACTOR; NY ESO 1 ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; RIBOSOME PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSCRIPTION FACTOR PBX1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1;

BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CELL CYCLE PROGRESSION; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GENE FUSION; GENETIC MARKER; GENOMICS; HUMAN; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; GENETICS; MALE; PROSTATIC NEOPLASMS; URINE;

BIOMARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 85009965924     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 2014;120:3519-26.
3. Pashtan I, Chen MH, and D'Amico AV, The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml. Cancer Epidemiol. 2014; 38: 613-8
4. Moyer VA, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
5. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419-26.
6. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
7. Shariat SF, Canto EI, Kattan MW, and Slawin KM, Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004;6:58-72.
8. Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J et al. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 2012;110:36-42.
9. Ankerst DP, Miyamoto R, Nair PV, Pollock BH, Thompson IM, Parekh DJ. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. J Urol 2009;181:2071-5; discussion 2076.
10. Boniol M, Autier P, Perrin P, Boyle P. Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study. Urology 2015;85:1117-22.
11. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
12. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009;27:398-403.
13. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 2007;70:685-90.
14. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostatespecific antigen velocity in prostate cancer detection. J Natl Cancer Inst 2011;103:462-9.
15. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ. Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. BJU Int 2012;109:508-13; discussion 513-4.
16. Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. J Urol 2014. 191:629-37.
17. Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, and Catalona WJ, Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007;177:505-9.
18. Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhayani SB et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 2007;69:1121-7.
19. Magheli A, Hinz S, Hege C, Stephan C, Jung K, Miller K et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010;183:126-31.
20. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170(6 Pt 1):2274-8.
21. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297-305.
22. Ng MK, Van As N, Thomas K, Woode-Amissah R, Horwich A, Huddart R et al. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. BJU Int 2009;103:872-6.
23. Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012;188:1131-6.
24. Vasarainen H, Salman J, Salminen H, Valdagni R, Pickles T, Bangma C et al. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J Urol 2015 [Epub ahead of print].
25. Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014;140:257-63.
26. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W et al. A precursor form of prostatespecific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60:756-9.
27. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
28. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729-39.
29. Bruzzese D, Mazzarella C, Ferro M, Perdona S, Chiodini P, Perruolo G et al. Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl Res 2014;164:444-51.
30. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
31. Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 2013;112:313-21.
32. Lazzeri M, Abrate A, Lughezzani G, Gadda GM, Freschi M, Mistretta F et al. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology 2014;83:606-12.
33. Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T et al. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Eur Urol 2014;pii:S0302-2838(14)00686-1.
34. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232-9.
35. Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev 2010;20:255-61.
36. Voigt JD, Zappala SM, Vaughan ED, and Wein AJ, The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate 2014;74:250-9.
37. Carlsson S, Maschino A, Schroder F, Bangma C, Steyerberg EW, van der Kwast T et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur Urol 2013;64:693-9.
38. Bjartell AS, Next-generation prostate-specific antigen test: ready to use? Eur Urol 2013;64:700-2.
39. Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW et al. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol 2014;66:1109-15.
40. Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010;10:635.
41. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010;103:708-14.
42. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010;116:2612-20.
43. Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
44. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 2006;13:238-43.
45. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
46. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Urol 2014;pii:S0302-2838(14)01035-5.
47. Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M et al. Improving the specificity of screening for lethal prostate cancer using prostatespecific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol 2015 [Epub ahead of print].
48. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
49. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8.
50. Grivennikov SI, Greten FR, and Karin M, Immunity, inflammation, and cancer. Cell 2010;140:883-99.
51. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009;115:3879-86.
52. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
53. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-67.
54. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010;183:534-8.
55. Vlaeminck-Guillem V, Ruffion A, Andre J, Devonec M, Paparel P, Urinary prostate cancer 3 test: toward the age of reason? Urology 2010;75:447-53.
56. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013;190:64-9.
57. Luo Y, Gou X, Huang P, Mou C. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis. Chin Med J (Engl) 2014;127:1768-74.
58. Bollito E, De Luca S, Cicilano M, Passera R, Grande S, Maccagnano C et al. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy. Anal Quant Cytol Histol 2012;34:96-104.
59. Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012;413:1274-8.
60. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011;59:96-105.
61. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al. Frequent overexpression of ETSrelated gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
62. Falzarano SM and Magi-Galluzzi C, ERG protein expression as a biomarker of prostate cancer. Biomark Med 2013;7:851-65.
63. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
64. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
65. Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer 2012;48:538-46.
66. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-63.
67. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, Tillmans L et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26:3930-6.
68. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-44.
69. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-5.
70. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-5.
71. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-43.
72. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
73. Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A et al. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate 2013;73:905-12.
74. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-6.
75. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-403.
76. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y et al. Frequent overexpression of ETSrelated gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
77. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-400.
78. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: pathological features and ERG fusion status. J Urol 2011;185:489-94.
79. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-5.
80. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-3.
81. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013;31:566-71.
82. Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O, Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate 2013;73:242-9.
83. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.
84. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, and Schalken JA, Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.
85. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3:94ra72.
86. Heichman KA, Warren JD, DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012;50:1707-21.
87. Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W et al. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J Urol 2013;189:329-35.
88. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate 2012;72:1248-61.
89. Van Neste L, Bigley J, Toll A, Otto G, Clark J, Delree P et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol 2012;12:16.
90. Stewart GD, Van Neste L, Delvenne P, Delree P, Delga A, McNeill SA et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol 2013;189:1110-6.
91. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014;192:1081-7.
92. Parr RL, Dakubo GD, Thayer RE, McKenney K, Birch-Machin MA, Mitochondrial DNA as a potential tool for early cancer detection. Hum Genomics 2006;2:252-7.
93. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A et al. Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens. Am J Clin Pathol 2008;129:57-66.
94. Robinson K, Creed J, Reguly B, Powell C, Wittock R, Klein D et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 2010;13:126-31.
95. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A et al. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006;8:312-9.
96. Parr RL, Mills J, Harbottle A, Creed JM, Crewdson G, Reguly B et al. Mitochondria, prostate cancer, and biopsy sampling error. Discov Med 2013;15:213-20.
97. Verschoor ML, Ungard R, Harbottle A, Jakupciak JP, Parr RL, Singh G. Mitochondria and cancer: past, present, and future. Biomed Res Int 2013;2013:612369.
98. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J et al. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013;14:690.
99. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550-60.
100. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. Eur Urol 2014;pii: S0302-2838(14)01213-5.
101. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55.
102. Cuzick J, Berney DM, Fisher G, Mesher D, Moller H, Reid JE et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9.
103. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:848-53.
104. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-34.
105. Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014;192:409-14.
106. Cuzick J. Prognostic value of a cell cycle progression score for men with prostate cancer. Recent Results Cancer Res 2014;202:133-40.
107. Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2014;pii: S0302-2838(14)01221-4.
108. Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br J Cancer 2014;111:1201-12.
109. Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clin Cancer Res 2015 [Epub ahead of print].
110. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011 59:893-9.
111. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013. 8:e66855.
112. Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015;67:778-86.
113. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008;3:e2318.
114. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013;190:2047-53.
115. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:1038-46.
116. Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2014;17:64-9.
117. Blute ML, Bergstralh EJ, Iocca A, Scherer B, and Zincke H, Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
118. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035-41.
119. Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013;4:600-9.
120. Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D et al. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int 2015;115:419-29.
121. Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C et al. Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study. Curr Med Res Opin 2014;30:1547-56.
122. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467-79.
123. Gomella LG and Oliver Sartor A, The current role and limitations of surrogate endpoints in advanced prostate cancer. Urol Oncol 2014;32:28 e1-9.
124. Antonarakis ES, Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert Rev Anticancer Ther 2015;15:143-5.
125. Antonarakis ES, Lu C, Chen Y, Luber B, Wang H, Nakazawa M et al. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). in 2015 Genitourinary Cancers Symposium. 2015. Orlando, Florida.
126. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
127. Nakazawa M, Antonarakis ES, and Luo J, Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 2014;5:265-73.
128. Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32:1136-42.
129. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
130. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20:27-33.
131. Miyamoto DT, Sequist LV, Lee RJ. Circulating tumour cells-monitoring treatment response in prostate cancer. Nat Rev Clin Oncol 2014;11:401-12.
132. Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V et al. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol 2015.
133. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.